Rockefeller Capital Management
PRQR icon

Rockefeller Capital Management’s ProQR Therapeutics PRQR Stock Holding History

Rockefeller Capital Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-34
Closed -$69 – 4839
2025
Q4 		$69 Hold
34
– – ﹤0.01% 4637
2025
Q3 		$72 Buy
+34
New +$74 ﹤0.01% 4384

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Rockefeller Capital Management's PRQR Position: Q1 2026 in Review

Rockefeller Capital Management sold out of ProQR Therapeutics (PRQR) in Q1 2026, closing a stake of 34 shares — an estimated $69 sold.

Rockefeller Capital Management first reported a position in PRQR in Q3 2025 and held it in 2 quarters. The position peaked at $72 in Q3 2025. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

  • Rockefeller Capital Management reported no remaining ProQR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Rockefeller Capital Management sold 34 ProQR Therapeutics shares in Q1 2026, an estimated $69.
  • Rockefeller Capital Management first reported a position in ProQR Therapeutics in Q3 2025 and held it in 2 quarters.
  • Rockefeller Capital Management's ProQR Therapeutics position peaked at $72 in Q3 2025.
  • 69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.